5:28 Liquid Biopsy in Lung Cancer Decreases Time to Treatment June 20, 2022 • Oncology Miguel Garcia-Pardo, MD, of @pmcancercentre, discusses #liquidbiopsy in #lungcancer.
18:03 The Impact of Biologic Therapy on IBD Surgical Management March 11, 2022 • Ulcerative Colitis Content Hub @JasonFrischerMD of @CincyChildrens discusses the impact of biologics on IBD surgery.
51:47 Podcast: Data From the True North Study March 9, 2022 • Ulcerative Colitis Content Hub @KakodkarSamir discusses #ozanimod based on the #TRUENORTH study.
2:58 Vitamin D May Reduce Risk of Autoimmune Disorders, Including Rheumatoid Arthritis March 8, 2022 • Rheumatoid Arthritis Content Hub JoAnn Manson, MD, MPH, DrPH, of @BrighamWomens, discusses results of the #VITAL trial.
9:43 Phase 2b Data for Guselkumab in Ulcerative Colitis March 7, 2022 • Ulcerative Colitis Content Hub Axel Dignass, MD, PhD, Goethe University, discusses findings from the phase 2b QUASAR study.
5:45 Recent Study on Combination of Guselkumab and Golimumab in Ulcerative Colitis March 3, 2022 • Ulcerative Colitis Content Hub Bruce Sands, MD, MS, from @IcahnMountSinai, discusses a combination therapy in #ulcerativecolitis.
2:41 Use of Electronic Health Records to Assess Risk for Lysosomal Storage Disease February 23, 2022 • Pompe Disease Content Hub @DNADirectedDawn, of @EmoryGCTP, discusses severity #scoring systems as #screening for #lysosomalstoragediseases.
4:35 Safety and Efficacy of Asciminib in Third-Line Treatment for CML January 30, 2022 • CML Content Hub @mjmauroMD, of @MSKCancerCenter, discusses #third-line treatment for #CML.
2:12 Well Tolerated in Preliminary Study: Pembrolizumab + TKIs in CML Patients With Persistent Detectible MRD January 19, 2022 • CML Content Hub @Dr_AmerZeidan, of @Yale, discusses #safety of #pembrolizumab plus #TKIs in #CML.
2:00 Fractional Flow Reserve-Guided Percutaneous Coronary Intervention Did Not Meet Noninferiority Compared to Coronary Artery Bypass Surgery December 23, 2021 • Cardiology Dr William Fearon of @StanfordUniversity discusses FAME3 trial outcomes.
